Patents by Inventor Fu-Gang Zhu

Fu-Gang Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20180044669
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Inventors: Sudhir AGRAWAL, Wayne JIANG, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • Compositions for inhibiting checkpoint gene expression and uses thereof
    Patent number: 9828601
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: November 28, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
    Publication number: 20170268006
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • Toll-like receptor 9 antagonist and methods of use thereof
    Patent number: 9688993
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: June 27, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • COMPOSITIONS FOR INHIBITING NLRP3 GENE EXPRESSION AND USES THEREOF
    Publication number: 20170145412
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating NLRP3 mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 25, 2017
    Inventors: Weiwen Jiang, Mallikarjuna R. Putta, Fu-Gang Zhu, Jillian M. DiMuzio, Lakshmi Bhagat, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING DUX4 GENE EXPRESSION AND USES THEREOF
    Publication number: 20170009230
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating DUX4 mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: July 7, 2016
    Publication date: January 12, 2017
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Fu-Gang Zhu
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20160251652
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
    Publication number: 20160237437
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Application
    Filed: February 11, 2016
    Publication date: August 18, 2016
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
    Patent number: 8987221
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 24, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
    Patent number: 8853177
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9
    Publication number: 20110171209
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 1, 2010
    Publication date: July 14, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES
    Publication number: 20110123540
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
    Type: Application
    Filed: November 23, 2010
    Publication date: May 26, 2011
    Inventors: Daqing Wang, Ekambar Kandimalla, Sudhir Agrawal, Fu-Gang Zhu
  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Publication number: 20100166805
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: December 3, 2009
    Publication date: July 1, 2010
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar Kandimalla
  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Patent number: 7713535
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 11, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar R. Kandimalla
  • Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto
    Publication number: 20100098685
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Application
    Filed: October 6, 2009
    Publication date: April 22, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
    Publication number: 20050222072
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
    Type: Application
    Filed: February 17, 2005
    Publication date: October 6, 2005
    Inventors: Daqing Wang, Ekambar Kandimalla, Sudhir Agrawal, Fu-Gang Zhu
  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Publication number: 20050130918
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: May 24, 2004
    Publication date: June 16, 2005
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Fu-Gang Zhu